CD3 CAR NK-92 cells, generated by genetic engineering of NK-92 cells using the C3-4-1BB-CD28-CD3ζ construction, specifically eliminated CD3+ lymphoma/leukemic cells, suppressed tumor growth and significantly prolonged survival in a CD3+ lymphoma xenograft model (193). Here, CD28 is linked to lymphoma.